Granules India CEO K V Sitaram Rao resigns
Dr. Rao has over 29 years of experience in manufacturing, R&D, business operations, and customer service
Dr. Rao has over 29 years of experience in manufacturing, R&D, business operations, and customer service
Net profit doubled to Rs. 10.8 crore, with PAT margin expanding by 560 bps to 14.3%, reflecting strong operational execution
The scheme aims to avoid disruption in supply of critical active pharmaceutical ingredients (APIs) used to make critical drugs
Revenue increased 11.4 per cent to Rs. 8,545 crore
3SBio will receive a payment of $1.25 billion. Pfizer will also make a $100 million equity investment in 3SBio
This partnership aims to address the growing demand for high-quality diagnostics in metropolitan areas
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
Based on the CRL, the STARGLO data do not provide sufficient evidence to support the proposed second-line DLBCL indication in the US patient population
This collaboration aims to bridge India’s talent and translational gap in this rapidly growing field by equipping professionals with practical expertise in the manufacturing of advanced therapies.
Subscribe To Our Newsletter & Stay Updated